Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes
Diabetes Obesity and Cardiometabolic CARE · 01.07.2026 · 1 (4) · 725-731
DOI: 10.2337/doc26-0019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes Obesity and Cardiometabolic CARE, online erschienen am 14.07.2026. Verfasst von Cody Chan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kovler Diabetes Center, The University of Chicago Medicine, Chicago, IL. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Diabetes Association.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Adolescents and young adults with type 2 diabetes face socioeconomic barriers to initiation of guideline-directed therapy. Ambulatory care pharmacists are well positioned to address medication access and prescribing gaps through interdisciplinary care models. This article describes the implementation and outcomes of a pharmacist-led pre-visit planning quality improvement initiative to optimize prescribing of guideline-directed therapies in adolescents and young adults with type 2 diabetes. RESEARCH DESIGN AND METHODS A pharmacist-driven quality improvement initiative was implemented at The University of Chicago Medicine Kovler Diabetes Center in October 2022. Patients aged 10–44 years with type 2 diabetes and HbA1c >7% were identified prior to scheduled endocrinology visits with use of electronic medical record reports. Pharmacists conducted pre-visit chart reviews, assessed eligibility for sodium–glucose cotransporter 2 inhibitors and glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonists, evaluated insurance coverage, and communicated recommendations to providers using standardized STEP (Supporting Teamwork that Empowers Patients) notes. Plan-Do-Study-Act (PDSA) cycles were used to refine workflow and prescribing outcomes. RESULTS A total of 93 unique patients received pharmacist STEP notes between October 2022 and May 2025. Providers prescribed recommended therapy for 38% of patients; 34% of recommendations were not implemented due to missed visits. Among patients with follow-up data, mean HbA1c decreased from 8.7% at baseline to 7.8% at 3–6 months. Prescribing rates improved across successive PDSA cycles. CONCLUSIONS Pharmacist-led pre-visit planning may improve access to guideline-directed therapy and may support glycemic improvement in adolescents and young adults with type 2 diabetes. This interdisciplinary care model addresses medication access barriers and therapeutic inertia in high-risk populations.
Autor:innen und Institutionen
- Kovler Diabetes Center, The University of Chicago Medicine, Chicago, IL.
ORCID-Profile: Cody Chan, Katie O'Sullivan
Förderung
- American Diabetes Association
Zitieren
APA
Chan, C., O'Sullivan, K., Murphy, E., Mossing, T., Pop, D., & Thomas, C. C. (2026). Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes. Diabetes Obesity and Cardiometabolic CARE, 1(4), 725-731. https://doi.org/10.2337/doc26-0019
Vancouver
Chan C, O'Sullivan K, Murphy E, Mossing T, Pop D, Thomas CC. Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes. Diabetes Obesity and Cardiometabolic CARE. 2026;1(4):725-731. doi:10.2337/doc26-0019
BibTeX
@article{Chan2026,
author = {Chan, Cody and O'Sullivan, Katie and Murphy, Elizabeth and Mossing, Taylor and Pop, Diana and Thomas, Celeste C},
title = {Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes},
journal = {Diabetes Obesity and Cardiometabolic CARE},
year = {2026},
volume = {1},
number = {4},
pages = {725--731},
doi = {10.2337/doc26-0019}
}
EUVIMED